En­her­tu wins an­oth­er breast can­cer ap­proval, as As­traZeneca and Dai­ichi Sankyo pre­pare to cor­ner the mar­ket

As­traZeneca and Dai­ichi Sankyo’s En­her­tu fran­chise keeps chug­ging along, as the blos­som­ing an­ti­body-drug con­ju­gate racked up an­oth­er ap­proval ear­ly Thurs­day morn­ing.

En­her­tu is now OK …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER